On the personal utility of Alzheimer's disease-related biomarker testing in the research context

Journal of Medical Ethics
E BunnikM Schermer

Abstract

Many healthy volunteers choose to take part in Alzheimer's disease (AD) prevention studies because they want to know whether they will develop dementia-and what they can do to reduce their risk-and are therefore interested in learning the results of AD biomarker tests. Proponents of AD biomarker disclosure often refer to the personal utility of AD biomarkers, claiming that research participants will be able to use AD biomarker information for personal purposes, such as planning ahead or making important life decisions. In this paper, the claim that AD biomarkers have personal utility for asymptomatic individuals is critically assessed. It demonstrates that in the absence of clinical validity, AD biomarkers cannot have personal utility and do not serve research participants' autonomy. Over the next few years, many research groups will be confronted with participants' preferences to learn the results of AD biomarker tests. When researchers choose to make results available upon explicit request, they should ensure adequate information provision and education, notably on the uncertain clinical significance of AD biomarker information. Routine disclosure of AD biomarkers to cognitively unimpaired individuals in research settings can...Continue Reading

References

Aug 11, 2005·JAMA : the Journal of the American Medical Association·David I Shalowitz, Franklin G Miller
Jul 23, 2009·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Scott D GrosseMuin J Khoury
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Oct 12, 2010·Lancet Neurology·Bruno DuboisPhilip Scheltens
Jul 14, 2011·Genetic Testing and Molecular Biomarkers·Ilona M KopitsRobert C Green
Jan 30, 2013·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Keith A JohnsonWilliam H Thies
Jan 31, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Keith A JohnsonUNKNOWN Amyloid Imaging Taskforce
Apr 16, 2013·Progress in Neurobiology·J Scott Roberts, Wendy R Uhlmann
Aug 24, 2013·Neurology·Melanie B ShulmanJason Karlawish
May 7, 2014·Journal of Medical Ethics·Effy Vayena
May 23, 2014·Lancet Neurology·Bruno DuboisJeffrey L Cummings
May 30, 2014·Journal of Medical Ethics·Eline M BunnikMaartje H N Schermer
Aug 31, 2014·Mayo Clinic Proceedings·Richard J CaselliJason S Robert
Dec 20, 2015·The Lancet. Psychiatry·Craig W RitchieUNKNOWN European Prevention of Alzheimer's Dementia (EPAD) Consortium
Apr 23, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Gil D RabinoviciMaria C Carrillo
Jun 3, 2016·Journal of Medical Ethics·Matthew Wai Heng Chung, Joseph Chi Fung Ng
Dec 7, 2016·JAMA : the Journal of the American Medical Association·Johannes J M van Delden, Rieke van der Graaf
Feb 27, 2017·Journal of Medical Internet Research·John Mark Michael Rumbold, Barbara Pierscionek
Apr 1, 2017·Journal of Genetic Counseling·Aysegül IbislerSabine Hoffjan
Feb 27, 2018·Journal of Alzheimer's Disease : JAD·Richard MilneCarol Brayne

❮ Previous
Next ❯

Citations

Nov 27, 2019·Current Opinion in Psychiatry·Miguel E RenteríaAmaranta Manrique de Lara
May 7, 2019·Alzheimer Disease and Associated Disorders·Melissa J ArmstrongC D Mullins
Dec 29, 2020·Journal of Alzheimer's Disease : JAD·Krista TrompMaartje H N Schermer
Dec 19, 2020·Journal of Alzheimer's Disease : JAD·Dorothee HorstkötterSebastian Köhler
Feb 18, 2021·Health Sociology Review : the Journal of the Health Section of the Australian Sociological Association·James Rupert Fletcher
Feb 27, 2021·Sociology of Health & Illness·Karen Dam Nielsen, Marianne Boenink
Mar 6, 2021·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Claire M EricksonLindsay R Clark
Jul 23, 2021·Journal of Medical Ethics·Zümrüt Alpinar-SencanPerla Werner
Oct 13, 2021·Alzheimer's Research & Therapy·Leonie N C VisserJosé Luis Molinuevo

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

© 2022 Meta ULC. All rights reserved